These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32202151)

  • 1. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
    Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
    Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary tract infections in patients with diabetes treated with dapagliflozin.
    Johnsson KM; Ptaszynska A; Schmitz B; Sugg J; Parikh SJ; List JF
    J Diabetes Complications; 2013; 27(5):473-8. PubMed ID: 23849632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
    Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
    Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of sodium-glucose cotransporter-2 inhibitors as add-on to metformin treatment in the management of type 2 diabetes mellitus: A meta-analysis.
    Li J; Gong Y; Li C; Lu Y; Liu Y; Shao Y
    Medicine (Baltimore); 2017 Jul; 96(27):e7201. PubMed ID: 28682870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis.
    McNeill AM; Davies G; Kruger E; Kowal S; Reason T; Ejzykowicz F; Hannachi H; Cater N; McLeod E
    Diabetes Ther; 2019 Apr; 10(2):473-491. PubMed ID: 30689140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
    Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
    Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: A systematic literature review and Bayesian network meta-analysis of randomized controlled trials.
    Azharuddin M; Adil M; Ghosh P; Sharma M
    Diabetes Res Clin Pract; 2018 Dec; 146():180-190. PubMed ID: 30389620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.
    Wang H; Yang J; Chen X; Qiu F; Li J
    Clin Ther; 2019 Feb; 41(2):322-334.e11. PubMed ID: 30711143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis.
    Chen JY; Pan HC; Shiao CC; Chuang MH; See CY; Yeh TH; Yang Y; Chu WK; Wu VC
    Cardiovasc Diabetol; 2023 Oct; 22(1):290. PubMed ID: 37891550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials.
    Donnan JR; Grandy CA; Chibrikov E; PharmD CM; Aubrey-Bassler K; Johnston K; Swab M; Hache J; Curnew D; Nguyen H; Gamble JM
    CMAJ Open; 2018; 6(4):E594-E602. PubMed ID: 30530719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic literature review and network meta-analysis of sodium-glucose co-transporter inhibitors vs metformin as add-on to insulin in type 1 diabetes.
    Langford BE; Evans M; Haskins-Coulter T; O'Connor M; Cant HEO; Eddowes LA; Edmonds C; Tank A
    Diabetes Obes Metab; 2020 Jan; 22(1):39-50. PubMed ID: 31468649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors.
    Qiu M; Ding LL; Zhang M; Zhou HR
    Diab Vasc Dis Res; 2021; 18(2):14791641211011016. PubMed ID: 33887983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
    Willis M; Asseburg C; Neslusan C
    Diabetes Res Clin Pract; 2019 Feb; 148():222-233. PubMed ID: 30641163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
    Tang HL; Li DD; Zhang JJ; Hsu YH; Wang TS; Zhai SD; Song YQ
    Diabetes Obes Metab; 2016 Dec; 18(12):1199-1206. PubMed ID: 27407013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
    Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
    Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.